The chromogranin A- derived N-terminal peptide vasostatin-I

In vivo effects on cardiovascular variables in the rabbit

Silvestro Roatta, Magda Passatore, Matteo Novello, Barbara Colombo, Eleonora Dondossola, Mazher Mohammed, Gianni Losano, Angelo Corti, Karen B. Helle

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study is the first to report on vascular effect of the chromogranin A derived Vasostatin-I (CgA 1-76) in vivo. Cardiovascular parameters were recorded in 29 rabbits with sympathetically decentralized right carotid vascular bed. The recombinant human STA CgA 1-78 (VS-1) was infused at 480μg/kg over 25min. Group I was kept awake while groups II-V were anesthetized with Ketamine-xylazine. VS-1 was given alone in groups I-II while in presence of either phentolamine, phentolamine plus propranolol or hexamethonium in groups III-V.Serum VS-1 peaked at 2. μg/ml (200 nM) before onset of vascular effects and declined rapidly to ~. 200 ng/ml within 30 min. In all groups but III and IV VS-1 induced a brief vasoconstriction, being larger in intact than in sympathetically decentralized beds. The VS-1 induced vasoconstriction was not altered by hexamethonium but was abolished by phentolamine. In presence of the α-adrenergic blocker a long lasting vasodilatation, unaffected by propranolol, was apparent on both innervated and decentralized sides.In conclusion, VS-1 induced an α-adrenoceptor-mediated vasoconstriction presumably brought about by noradrenaline release from sympathetic nerves when infused at a dose giving an initial serum concentration of ~. 200 nM. This initial vasoconstriction masked a persistent adrenoceptor-independent vasodilatation, consistent with previous reports from in vitro models.

Original languageEnglish
Pages (from-to)10-20
Number of pages11
JournalRegulatory Peptides
Volume168
Issue number1-3
DOIs
Publication statusPublished - Jun 7 2011

Fingerprint

Chromogranin A
Vasoconstriction
Phentolamine
Rabbits
Blood Vessels
Hexamethonium
Peptides
Vasodilation
Propranolol
Adrenergic Receptors
Xylazine
Adrenergic Antagonists
Ketamine
Serum
Norepinephrine
vasostatin I

Keywords

  • Adrenergic blockades
  • Conscious animal
  • Ganglion blockade
  • Sympathetic nervous system
  • Vasoconstriction
  • Vasodilatation

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Roatta, S., Passatore, M., Novello, M., Colombo, B., Dondossola, E., Mohammed, M., ... Helle, K. B. (2011). The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. Regulatory Peptides, 168(1-3), 10-20. https://doi.org/10.1016/j.regpep.2011.02.015

The chromogranin A- derived N-terminal peptide vasostatin-I : In vivo effects on cardiovascular variables in the rabbit. / Roatta, Silvestro; Passatore, Magda; Novello, Matteo; Colombo, Barbara; Dondossola, Eleonora; Mohammed, Mazher; Losano, Gianni; Corti, Angelo; Helle, Karen B.

In: Regulatory Peptides, Vol. 168, No. 1-3, 07.06.2011, p. 10-20.

Research output: Contribution to journalArticle

Roatta, S, Passatore, M, Novello, M, Colombo, B, Dondossola, E, Mohammed, M, Losano, G, Corti, A & Helle, KB 2011, 'The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit', Regulatory Peptides, vol. 168, no. 1-3, pp. 10-20. https://doi.org/10.1016/j.regpep.2011.02.015
Roatta, Silvestro ; Passatore, Magda ; Novello, Matteo ; Colombo, Barbara ; Dondossola, Eleonora ; Mohammed, Mazher ; Losano, Gianni ; Corti, Angelo ; Helle, Karen B. / The chromogranin A- derived N-terminal peptide vasostatin-I : In vivo effects on cardiovascular variables in the rabbit. In: Regulatory Peptides. 2011 ; Vol. 168, No. 1-3. pp. 10-20.
@article{ac2c72e37b6c4378bf193e81256aaa2b,
title = "The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit",
abstract = "This study is the first to report on vascular effect of the chromogranin A derived Vasostatin-I (CgA 1-76) in vivo. Cardiovascular parameters were recorded in 29 rabbits with sympathetically decentralized right carotid vascular bed. The recombinant human STA CgA 1-78 (VS-1) was infused at 480μg/kg over 25min. Group I was kept awake while groups II-V were anesthetized with Ketamine-xylazine. VS-1 was given alone in groups I-II while in presence of either phentolamine, phentolamine plus propranolol or hexamethonium in groups III-V.Serum VS-1 peaked at 2. μg/ml (200 nM) before onset of vascular effects and declined rapidly to ~. 200 ng/ml within 30 min. In all groups but III and IV VS-1 induced a brief vasoconstriction, being larger in intact than in sympathetically decentralized beds. The VS-1 induced vasoconstriction was not altered by hexamethonium but was abolished by phentolamine. In presence of the α-adrenergic blocker a long lasting vasodilatation, unaffected by propranolol, was apparent on both innervated and decentralized sides.In conclusion, VS-1 induced an α-adrenoceptor-mediated vasoconstriction presumably brought about by noradrenaline release from sympathetic nerves when infused at a dose giving an initial serum concentration of ~. 200 nM. This initial vasoconstriction masked a persistent adrenoceptor-independent vasodilatation, consistent with previous reports from in vitro models.",
keywords = "Adrenergic blockades, Conscious animal, Ganglion blockade, Sympathetic nervous system, Vasoconstriction, Vasodilatation",
author = "Silvestro Roatta and Magda Passatore and Matteo Novello and Barbara Colombo and Eleonora Dondossola and Mazher Mohammed and Gianni Losano and Angelo Corti and Helle, {Karen B.}",
year = "2011",
month = "6",
day = "7",
doi = "10.1016/j.regpep.2011.02.015",
language = "English",
volume = "168",
pages = "10--20",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The chromogranin A- derived N-terminal peptide vasostatin-I

T2 - In vivo effects on cardiovascular variables in the rabbit

AU - Roatta, Silvestro

AU - Passatore, Magda

AU - Novello, Matteo

AU - Colombo, Barbara

AU - Dondossola, Eleonora

AU - Mohammed, Mazher

AU - Losano, Gianni

AU - Corti, Angelo

AU - Helle, Karen B.

PY - 2011/6/7

Y1 - 2011/6/7

N2 - This study is the first to report on vascular effect of the chromogranin A derived Vasostatin-I (CgA 1-76) in vivo. Cardiovascular parameters were recorded in 29 rabbits with sympathetically decentralized right carotid vascular bed. The recombinant human STA CgA 1-78 (VS-1) was infused at 480μg/kg over 25min. Group I was kept awake while groups II-V were anesthetized with Ketamine-xylazine. VS-1 was given alone in groups I-II while in presence of either phentolamine, phentolamine plus propranolol or hexamethonium in groups III-V.Serum VS-1 peaked at 2. μg/ml (200 nM) before onset of vascular effects and declined rapidly to ~. 200 ng/ml within 30 min. In all groups but III and IV VS-1 induced a brief vasoconstriction, being larger in intact than in sympathetically decentralized beds. The VS-1 induced vasoconstriction was not altered by hexamethonium but was abolished by phentolamine. In presence of the α-adrenergic blocker a long lasting vasodilatation, unaffected by propranolol, was apparent on both innervated and decentralized sides.In conclusion, VS-1 induced an α-adrenoceptor-mediated vasoconstriction presumably brought about by noradrenaline release from sympathetic nerves when infused at a dose giving an initial serum concentration of ~. 200 nM. This initial vasoconstriction masked a persistent adrenoceptor-independent vasodilatation, consistent with previous reports from in vitro models.

AB - This study is the first to report on vascular effect of the chromogranin A derived Vasostatin-I (CgA 1-76) in vivo. Cardiovascular parameters were recorded in 29 rabbits with sympathetically decentralized right carotid vascular bed. The recombinant human STA CgA 1-78 (VS-1) was infused at 480μg/kg over 25min. Group I was kept awake while groups II-V were anesthetized with Ketamine-xylazine. VS-1 was given alone in groups I-II while in presence of either phentolamine, phentolamine plus propranolol or hexamethonium in groups III-V.Serum VS-1 peaked at 2. μg/ml (200 nM) before onset of vascular effects and declined rapidly to ~. 200 ng/ml within 30 min. In all groups but III and IV VS-1 induced a brief vasoconstriction, being larger in intact than in sympathetically decentralized beds. The VS-1 induced vasoconstriction was not altered by hexamethonium but was abolished by phentolamine. In presence of the α-adrenergic blocker a long lasting vasodilatation, unaffected by propranolol, was apparent on both innervated and decentralized sides.In conclusion, VS-1 induced an α-adrenoceptor-mediated vasoconstriction presumably brought about by noradrenaline release from sympathetic nerves when infused at a dose giving an initial serum concentration of ~. 200 nM. This initial vasoconstriction masked a persistent adrenoceptor-independent vasodilatation, consistent with previous reports from in vitro models.

KW - Adrenergic blockades

KW - Conscious animal

KW - Ganglion blockade

KW - Sympathetic nervous system

KW - Vasoconstriction

KW - Vasodilatation

UR - http://www.scopus.com/inward/record.url?scp=79955648504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955648504&partnerID=8YFLogxK

U2 - 10.1016/j.regpep.2011.02.015

DO - 10.1016/j.regpep.2011.02.015

M3 - Article

VL - 168

SP - 10

EP - 20

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -